- Price
- $89.90
- Day
- +0.13%
- Mkt Cap
- $51.76B
- 52W Range
- $72.30 – $96.29
- Volume
- 2.62M
- Beta
- 0.85
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.
128,603 Shares in Edwards Lifesciences Corporation $EW Acquired by Beacon Pointe Advisors LLC
Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 128,603 shares of the medical research company's stock, valued at approximately $11,632,000. A number of
Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW
Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made
Is EW Overvalued? DCF Says Worth $53
On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year
37,702 Shares in Edwards Lifesciences Corporation $EW Bought by EP Wealth Advisors LLC
EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company's stock, valued at approximately $3,410,000. Other institutional investors and hedge